The Intellectual Property Office of New Zealand (IPONZ) granted AskAt a Notice of Acceptance for a salt and crystal forms patent, dated June 24, 2024 for its CB2 agonist, AAT-730. The notice was issued in connection with Application Number 797451 (Filing Date: November 11, 2021). In addition to New Zealand, AskAt has been granted salt and crystal forms patents by Australia, Brazil, Canada, China, Japan, Korea, Mexico, and the U.S.